Workers' Compensation
Drug Trend Report

The 2018 myMatrixx Workers’ Compensation Drug Trend Report contains a comprehensive view of the latest drug trends. This report highlights the changes we saw for myMatrixx workers’ compensation clients in 2018 while looking at trends to anticipate what the future holds.

  • Opioids have dropped to second place on the list of most commonly dispensed drugs for many payers.
  • Egregiously priced compounds are now almost nonexistent.
  • We drove down both cost and unnecessary utilization of prescription drugs.

For the first time, our report combines both myMatrixx® and Express Scripts® data providing a more complete view of the industry than ever before. In addition, we are highlighting our Get Ahead of the Claim™ program, which has steered our clinical strategy for the past decade, by demonstrating its effectiveness as a pharmacovigilance program for all drugs of concern beyond opioids and compounds.


More than half of the plans myMatrixx managed reduced drug spending in 2018.

The overall reduction in utilization included a 15% reduction in opioid spending.


Almost two-thirds of myMatrixx clients spent less on opioids in 2018 compared to 2017.

What’s Next? Looking at the Trends

myMatrixx will continue to monitor the opioid crisis but is also focusing on other drugs of concern. Our pharmacovigilance program monitors and combats excessively priced drugs, identifies potential fraud and abuse and is a key factor in our 2018 results as we focus on avoiding unnecessary prescriptions.


There was an 18.5% increase in specialty medication spending for injured works in 2018.


There was a 19.2% increase in the use of HIV medication in 2018 for post-exposure prophylaxis.


The generic fill rate (GFR) across all myMatrixx workers’ compensation payers in 2018 was 85.6%.


Cost of prescriptions drugs filled through home delivery were 20.1% less than those filled at retail pharmacies.

2018 Workers' Compensation

  • Driving down drug utilization and spending
  • Turning the tide on opioid use
  • Managing the rising use of specialty therapies
  • Exploring future pharmacy-related trends